Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use - PubMed

Affiliations

• PMID: 8528172

Clinical Trial

Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use

H M Lazarus et al. Bone Marrow Transplant. 1995 Oct.

Abstract

We report a phase I trial to determine the feasibility of collection, ex vivo culture-expansion and intravneous infusion of human bone marrow-derived progenitor stromal cells (mesenchymal progenitor cells (MPCs)). Ten milliliter bone marrow samples were obtained from 23 patients with hematologic malignancies in complete remission. Bone marrow mononuclear cells were separated and adherent cells were culture-expanded in vitro for 4-7 weeks. Autologous MPCs were reinfused intravenously and a bone marrow examination repeated 2 weeks later for histologic assessment and in vitro hematopoietic cultures. Patient age ranged from 18 to 68 years and 12 subjects previously had undergone an autologous or syngeneic bone marrow transplant 4-52 months prior to collection of MPCs. A median of 364 x 10(6) nucleated bone marrow cells (range: 103 to 1004 x 10(6)) were used for ex vivo expansion. Median number of MPCs which were obtained after ex vivo culture expansion was 59.0 (range: 1.1 to 347 x 10(6)) representing a median cell doubling of 16,000-fold (13 doublings). Fifteen of 23 patients completed the ex vivo expansion and underwent MPC infusion. Time to infusion of MPCs after collection ranged from 28 to 49 days. Five patients in each of three groups were given 1, 10 and 50 x 10(6) MPCs. No adverse reactions were observed with the infusion of the MPCs. MPCs obtained from cancer patients can be collected, expanded in vitro and infused intravenously without toxicity.(ABSTRACT TRUNCATED AT 250 WORDS)

Similar articles

• Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy.

  Engelhardt M, Douville J, Behringer D, Jähne A, Smith A, Henschler R, Lange W. Engelhardt M, et al. Bone Marrow Transplant. 2001 Feb;27(3):249-59. doi: 10.1038/sj.bmt.1702788. Bone Marrow Transplant. 2001. PMID: 11277172

• Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections.

  Lazarus HM, Haynesworth SE, Gerson SL, Caplan AI. Lazarus HM, et al. J Hematother. 1997 Oct;6(5):447-55. doi: 10.1089/scd.1.1997.6.447. J Hematother. 1997. PMID: 9368181

• Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.

  Gehling UM, Ryder JW, Hogan CJ, Hami L, McNiece I, Franklin W, Williams S, Helm K, King J, Shpall EJ. Gehling UM, et al. Exp Hematol. 1997 Oct;25(11):1125-39. Exp Hematol. 1997. PMID: 9328449

• Cell processing engineering for ex-vivo expansion of hematopoietic cells.

  Takagi M. Takagi M. J Biosci Bioeng. 2005 Mar;99(3):189-96. doi: 10.1263/jbb.99.189. J Biosci Bioeng. 2005. PMID: 16233777 Review.

• [Collection of hematopoietic progenitor cells from healthy donors].

  Bojanić I, Cepulić BG, Mazić S. Bojanić I, et al. Acta Med Croatica. 2009 Jun;63(3):237-44. Acta Med Croatica. 2009. PMID: 19827352 Review. Croatian.

Cited by

• Mesenchymal Stem Cells in the Pathogenesis and Therapy of Autoimmune and Autoinflammatory Diseases.

  Zaripova LN, Midgley A, Christmas SE, Beresford MW, Pain C, Baildam EM, Oldershaw RA. Zaripova LN, et al. Int J Mol Sci. 2023 Nov 7;24(22):16040. doi: 10.3390/ijms242216040. Int J Mol Sci. 2023. PMID: 38003230 Free PMC article. Review.

• Different Levels of Autophagy Activity in Mesenchymal Stem Cells Are Involved in the Progression of Idiopathic Pulmonary Fibrosis.

  Tao H, Lv Q, Zhang J, Chen L, Yang Y, Sun W. Tao H, et al. Stem Cells Int. 2024 Feb 15;2024:3429565. doi: 10.1155/2024/3429565. eCollection 2024. Stem Cells Int. 2024. PMID: 38390035 Free PMC article. Review.

• MSCs Become Collagen-Type I Producing Cells with Different Phenotype in Allogeneic and Syngeneic Bone Marrow Transplantation.

  Rusch RM, Ogawa Y, Sato S, Morikawa S, Inagaki E, Shimizu E, Tsubota K, Shimmura S. Rusch RM, et al. Int J Mol Sci. 2021 May 5;22(9):4895. doi: 10.3390/ijms22094895. Int J Mol Sci. 2021. PMID: 34063118 Free PMC article.

• Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.

  Kuçi Z, Bönig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, Škifić M, Michel K, Eising B, Lucchini G, Bakhtiar S, Greil J, Lang P, Basu O, von Luettichau I, Schulz A, Sykora KW, Jarisch A, Soerensen J, Salzmann-Manrique E, Seifried E, Klingebiel T, Bader P, Kuçi S. Kuçi Z, et al. Haematologica. 2016 Aug;101(8):985-94. doi: 10.3324/haematol.2015.140368. Epub 2016 May 12. Haematologica. 2016. PMID: 27175026 Free PMC article.

• Applying stem cell therapy in intractable diseases: a narrative review of decades of progress and challenges.

  Brianna, Ling APK, Wong YP. Brianna, et al. Stem Cell Investig. 2022 Sep 30;9:4. doi: 10.21037/sci-2022-021. eCollection 2022. Stem Cell Investig. 2022. PMID: 36238449 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database